Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level

NCT04133909 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

806

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

BIOLOGICAL: Mepolizumab
DRUG: Placebo

Sponsor

GlaxoSmithKline

Collaborators

[object Object]